| Product Name | Liraglutide |
| Synonyms | Liraglutide (free base); NN2211; (Lys(γ-Glu-palmitoyl)26, Arg34)-GLP-1(7-37); GLP-1 analogue |
| CAS Number | 204656-20-2 |
| Peptide Backbone | [Arg34]-GLP-1(7-37); 31-residue chain |
| Sequence (3-Letter) | H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(acyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH |
| Side-Chain Modification | Lys26 acylated with a γ-glutamic acid (γ-Glu) spacer and a C16 fatty acid (palmitic acid) |
| Molecular Formula | C₁₇₂H₂₆₅N₄₃O₅₁ |
| Molecular Weight | 3751.2 |
| Category | Drug Peptide – GLP-1 receptor agonist (peptide API / reference standard) |
| Purity | ≥98% (by HPLC); pharmaceutical-grade and reference-standard specifications available |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate by default; other salt forms on request |
| Water Content | Per specification (Karl Fischer) |
| Related Substances | Controlled per specification; individual impurity reference standards available |
| Storage | -20°C, desiccated, protected from light |
| Available Scale | mg – kg (research, reference-standard, and development / API quantities) |
| QC Documentation | COA, HPLC, MS identity; extended API / regulatory documentation on request |
| Usage | For research and pharmaceutical manufacturing or analytical development use only, including as a reference standard or active pharmaceutical ingredient for licensed manufacturers. Not for human or veterinary use; not for sale to patients or individuals. Customers are responsible for regulatory and intellectual-property compliance in their territory. |
Liraglutide is a long-acting GLP-1 receptor agonist, an acylated peptide analogue of human glucagon-like peptide-1 (GLP-1), with CAS 204656-20-2 and the molecular formula C172H265N43O51. Its backbone is a thirty-one-residue GLP-1 analogue with an arginine at position thirty-four, and a lysine side chain acylated with a glutamic-acid spacer and a C16 palmitic-acid chain that binds albumin and extends its duration. We make it in-house and supply it as a lyophilized powder for research and pharmaceutical manufacturing use.
Liraglutide works by binding and activating the GLP-1 receptor, a G-protein-coupled receptor. Its palmitic-acid side chain binds reversibly to serum albumin, which slows absorption and protects it from breakdown, extending how long it stays active compared with native GLP-1. This is the pharmacology behind the approved GLP-1 medicines for type 2 diabetes and weight management. The material we supply is for research and pharmaceutical manufacturing, is not for human or veterinary use, is not for sale to patients, and we make no health, weight-loss, or therapeutic claims.
Both are acylated GLP-1 analogues, but they differ in their modifications. Liraglutide carries a C16 palmitic-acid chain on a short glutamic-acid spacer and keeps the native residue at position eight, giving a half-life of about half a day and once-daily use. Semaglutide uses a longer C18 diacid chain on an extended spacer plus an Aib substitution at position eight, which gives a much longer half-life. We supply both as research and manufacturing materials, and the differences mainly matter for synthesis, analysis, and reference-standard work.
We supply Liraglutide as a synthetic peptide at high HPLC purity with a certificate of analysis, an HPLC chromatogram, and mass-spec identity confirmation. Pharmaceutical-grade and reference-standard specifications are available, including controlled related substances and extended documentation for regulatory and analytical work. Salt form, purity, and quantity can be set to your specification.
No. Liraglutide supplied by SynPeptide is a raw material for research and pharmaceutical development and manufacturing only. It is not a finished medicine, it is not for human or veterinary use, and it is not sold to patients or individuals for personal use. Any clinical or commercial medicinal use is the responsibility of an appropriately licensed party and is subject to the relevant regulatory approvals.
Liraglutide (CAS 204656-20-2) is a long-acting GLP-1 receptor agonist and a well-established peptide drug substance in metabolic medicine. It is an acylated analogue of human glucagon-like peptide-1 (GLP-1) and is the active peptide behind approved once-daily GLP-1 medicines for type 2 diabetes and weight management. We supply it as a synthetic peptide for research and pharmaceutical manufacturing, including as a reference standard and active pharmaceutical ingredient for licensed development work. It is not supplied as a finished medicine and not for human use.
Liraglutide is a 31-residue GLP-1 analogue that keeps about 97% of the human GLP-1(7-37) sequence. It has one backbone change, an arginine in place of lysine at position 34, and the lysine at position 26 carries a side chain made of a single γ-glutamic acid spacer and a C16 fatty acid (palmitic acid). Its molecular formula is C172H265N43O51 and its molecular weight is about 3751.2. The arginine swap at position 34 ensures the palmitic acid attaches only at Lys26, and the fatty-acid chain drives reversible binding to serum albumin, which is the main reason the molecule lasts long enough for once-daily use.
Liraglutide is an agonist of the GLP-1 receptor, a G-protein-coupled receptor. Unlike semaglutide, it keeps the native residue at position 8, so it is still a substrate for the enzyme DPP-4; its long action comes mainly from strong albumin binding rather than from blocking DPP-4. This is provided as factual background; the material we supply is for research and pharmaceutical development, not for human or veterinary use, not for sale to patients, and carries no health or therapeutic claims.
Liraglutide and semaglutide are both acylated GLP-1 receptor agonists from the same design lineage, but their side chains differ. Liraglutide uses a C16 palmitic acid on a single glutamic-acid spacer and keeps the native residue at position 8, giving a half-life of roughly half a day. Semaglutide uses a longer C18 diacid on a γ-glutamate plus AEEA spacer and adds an Aib substitution at position 8, giving a much longer half-life. For analytical and process work these differences change the synthesis route, the impurity profile, and the reference standards needed, which is why the two are often handled side by side.
Liraglutide is a hybrid peptide: a long peptide chain plus a fatty-acid side-chain conjugation step, which makes its manufacture and quality control demanding. As a peptide synthesis and peptide CDMO provider, we work with liraglutide as an active pharmaceutical ingredient and as a reference standard, supporting analytical method development, related-substance and impurity profiling, and process development. Individual impurity and related-substance reference standards can be prepared alongside the main compound for regulatory and stability work.
Store the lyophilized peptide at -20°C, kept dry and protected from light. Because the molecule carries a fatty-acid side chain and an oxidation-sensitive tryptophan, handle it under inert gas where possible and protect it from strong oxidants. Liraglutide also tends to self-associate in solution, so prepare stock solutions in a suitable buffer, aliquot to avoid repeated freeze-thaw, and follow the certificate of analysis for lot-specific water content and storage guidance.
For comparative and method-development work we can supply liraglutide together with related GLP-1 analogues, sequence variants, and labelled forms, prepared through peptide modification and held under our drug peptides range. Sourcing a compound and its impurities or analogues from the same batch keeps purity, salt form, and counter-ion consistent across a study.
We make Liraglutide by solid-phase and hybrid synthesis, including the side-chain conjugation, and release it with a certificate of analysis, HPLC purity data, and mass-spectrometry identity confirmation, with grade and salt form set to your specification. Supply runs from milligram research and reference quantities through to development and larger batches, handled by our large-scale peptide synthesis and custom peptide synthesis capabilities. Material is supplied for research and pharmaceutical manufacturing use only; customers are responsible for the regulatory and intellectual-property requirements that apply in their territory.
